Donate

Intermittent ADT, Does It Increase A Man’s Risk Factors For Serious Side Effects?

Once again we see what seems to be logical isn’t necessarily the way it actually works!  In a surprising study result, it was shown that the use of intermittent androgen-deprivation therapy (IADT) for prostate cancer is not associated with fewer long-term adverse events than continuous ADT!  Who would have guessed? We all thought that intermittent [...]

*Does Avodart (Dutasteride) Allow Men on Intermittent Androgen Therapy To Have A Longer “Off Period”?

Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or to receive a placebo. All of the men were receiving intermittent androgen deprivation therapy (IADT), which was stopped at month [...]

Large Data Analysis Finds That Intermittent Hormone Therapy Is Equal to Continuous Therapy for Men Who Are Good Initial Responders

The Journal of Clinical Oncology, published an article by Niraula et al. that searched the general literature published through August 2012. They searched MEDLINE, EMBASE, the Cochrane Library, as well as most major conference proceedings. Their criteria for inclusion included randomized, controlled trials of intermittent hormone therapy (IADT) as compared to continuous hormone therapy (CADT) [...]

Dr. S. Meyers Posts a Video About Intermittent vs. Continuous Hormone Therapy for Men with Prostate Cancer and Bone Metastasis

On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy for men with advanced prostate cancer with bone metastasis is not [...]

Intermittent Androgen Deprivation (IAD)- No Longer Considered Experimental for Treating Men with Advanced Prostate Cancer

Changing the Standard of Care for Men with Recurrent and Advanced Prostate Cancer, Men receiving androgen deprivation therapy (ADT) for the treatment of advanced or metastatic prostate cancer know all to well the terrible side effects this treatment modality can cause. These side effects can include fatigue, hot flashes, mood swings, inability to concentrate as [...]

Changes of PSA Doubling Time is Associated with Disease Progression in Men with Biochemically Relapsed Prostate Cancer Treated with Intermittent Androgen Deprivation

Researchers at the The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland studied the relationship between the change of PSA doubling time (PSADT) and disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. They retrospectively analyzed the data from 96 men diagnosed with biochemically relapsed prostate cancer (BRPC) who [...]

Timing IADT, Can “On Cycle” Time Periods Predict Outcomes?

A study by Yu et al., of men with a rising PSA after failed radical prostatectomy or radiation therapy who were placed on intermittent androgen deprivation therapy (IADT) indicated that the length of their first “off cycle” correlates with their expected time to developing castrate resistant prostate cancer (CRPC) and to their prostate cancer-specific mortality. [...]

Go to Top